COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
| Autor: | Fabio Buttari, Federica Azzolini, Paolo Bellantonio, Ettore Dolcetti, Roberta Fantozzi, Diego Centonze, Antonio Bruno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19) Lymphocyte Antibodies Monoclonal Humanized Settore MED/26 Antibodies Multiple sclerosis 03 medical and health sciences 0302 clinical medicine Immune system Monoclonal Correspondence medicine Humans 030212 general & internal medicine Cladribine Humanized biology Disease modifying therapy business.industry SARS-CoV-2 COVID-19 General Medicine medicine.disease Vaccination medicine.anatomical_structure Neurology Immunology biology.protein Ocrelizumab Neurology (clinical) Antibody business Vaccine 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis and Related Disorders |
| ISSN: | 2211-0356 2211-0348 |
| Popis: | Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated after 3 months from the last dose with good immune response, one (under ocrelizumab) after 2 months, without developing an appropriate title of antibodies. This experience suggests that the discriminant for the response to the vaccine is not the lymphocyte count but the timing of the vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect